Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07898813

Title field or adapter rule

{'original_value': 'Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:21.937490+00:00

Published At

2026-10-27T00:00:00+00:00

Record Updated At

2026-10-27

Source Retrieved At

2026-10-31T22:17:25.750886+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer", "Resectable Pancreatic Ductal Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-27", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07898813"

protocolSection.identificationModule.officialTitle

"Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Pancreatic Cancer (protocolSection.conditionsModule.conditions)
• Resectable Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Cohort A Perioperative Daraxonrasib', 'Cohort B Perioperative Daraxonrasib'], 'description': 'Oral study drug taken once daily in 28-day cycles at a predetermined dose before surgery, and optionally again in the adjuvant setting after completion of adjuvant therapy.', 'name': 'Daraxonrasib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A Perioperative Daraxonrasib', 'Cohort B Perioperative Daraxonrasib'], 'description': 'Protocol-planned surgery performed after neoadjuvant daraxonrasib treatment and surgical planning.', 'name': 'Surgical Resection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A Perioperative Daraxonrasib', 'Cohort B Perioperative Daraxonrasib'], 'description': 'Post-surgery chemotherapy administered per institutional standard and investigator/physician discretion.', 'name': 'Adjuvant Chemotherapy', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A Perioperative Daraxonrasib', 'Cohort B Perioperative Daraxonrasib'], 'description': 'Post-surgery radiation therapy may be given with adjuvant chemotherapy according to institutional standard and investigator/physician discretion.', 'name': 'Adjuvant Radiation Therapy', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Daraxonrasib (protocolSection.armsInterventionsModule.interventions[].name)
• Adjuvant Chemotherapy (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.